AU2001287000A1 - Modified polypeptides stabilized in a desired conformation and methods for producing same - Google Patents

Modified polypeptides stabilized in a desired conformation and methods for producing same

Info

Publication number
AU2001287000A1
AU2001287000A1 AU2001287000A AU8700001A AU2001287000A1 AU 2001287000 A1 AU2001287000 A1 AU 2001287000A1 AU 2001287000 A AU2001287000 A AU 2001287000A AU 8700001 A AU8700001 A AU 8700001A AU 2001287000 A1 AU2001287000 A1 AU 2001287000A1
Authority
AU
Australia
Prior art keywords
conformation
protein
methods
desired conformation
producing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287000A
Inventor
Chafen Lu
Motomu Shimoaka
Timothy A. Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
BLOOD RES CENTER
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BLOOD RES CENTER, Immune Disease Institute Inc filed Critical BLOOD RES CENTER
Publication of AU2001287000A1 publication Critical patent/AU2001287000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.
AU2001287000A 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same Abandoned AU2001287000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22970000P 2000-09-01 2000-09-01
US60/229,700 2000-09-01
PCT/US2001/027227 WO2002018583A2 (en) 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same

Publications (1)

Publication Number Publication Date
AU2001287000A1 true AU2001287000A1 (en) 2002-03-13

Family

ID=22862353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287000A Abandoned AU2001287000A1 (en) 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same

Country Status (8)

Country Link
US (6) US7160541B2 (en)
EP (1) EP1315812B1 (en)
JP (1) JP5113314B2 (en)
AT (1) ATE448306T1 (en)
AU (1) AU2001287000A1 (en)
CA (1) CA2417432C (en)
DE (1) DE60140457D1 (en)
WO (1) WO2002018583A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927591B2 (en) * 2004-02-19 2011-04-19 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
US7081687B2 (en) * 2004-07-22 2006-07-25 Sprint Communications Company L.P. Power system for a telecommunications facility
US7240492B2 (en) * 2004-07-22 2007-07-10 Sprint Communications Company L.P. Fuel system used for cooling purposes
ATE555202T1 (en) 2004-08-16 2012-05-15 Immune Disease Inst Inc METHOD FOR DELIVERING RNA INTERFERENCE AND USES THEREOF
US20070018182A1 (en) * 2005-07-20 2007-01-25 Goldeneye, Inc. Light emitting diodes with improved light extraction and reflectivity
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
US8021668B2 (en) * 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
AU2007243370A1 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research, Inc. Method of producing immunoliposomes and compositions thereof
AU2007243412A1 (en) * 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
AU2007256780B2 (en) * 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
JP5396270B2 (en) * 2006-06-02 2014-01-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Protein surface remodeling
US20120328628A1 (en) * 2006-07-07 2012-12-27 The Regents Of The University Of California Antibodies to conformationally trapped proteins
JP2011523353A (en) * 2008-04-28 2011-08-11 プレジデント アンド フェロウズ オブ ハーバード カレッジ Overcharged protein for cell penetration
US8877893B2 (en) * 2008-12-29 2014-11-04 Children's Medical Center Corporation Stabilized low affinity conformation of integrins for drug discovery
JP2012525146A (en) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Overcharged protein for cell penetration
EP3326645B1 (en) * 2010-10-25 2020-03-18 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
CA2832106A1 (en) * 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
JP6240063B2 (en) 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド Histone deacetylase inhibitor
WO2014018979A1 (en) 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
WO2020205827A1 (en) * 2019-04-01 2020-10-08 Rush University Medical Center Reagents and assays using modified integrin domains
US11100297B2 (en) * 2019-04-15 2021-08-24 International Business Machines Corporation Provision of natural language response to business process query

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (en) 1986-04-09 2010-12-30 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
EP0303692A4 (en) 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5831036A (en) 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5512660A (en) 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
US5565550A (en) 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US5489533A (en) 1987-05-04 1996-02-06 Dana Farber Cancer Institute Isolated nucleic acid molecules encoding ICAM-2
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5395929A (en) 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
EP0364690A3 (en) 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6511664B1 (en) 1989-03-09 2003-01-28 Dana Farber Cancer Institute Intercellular adhesion molecule—2 and its binding ligands
US6777191B1 (en) 1989-03-16 2004-08-17 Center For Blood Research, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in diagnosis of viral infection
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
KR100226158B1 (en) 1989-07-25 1999-10-15 스티븐 에이. 서윈. 엠.디. Homologous recombination for universal donor cells and chimeric mammalian hosts
NZ236792A (en) 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
MA22668A1 (en) 1990-07-10 1993-07-01 Smithkline Beecham Corp PROCESS FOR THE PREPARATION OF OXAMIDES.
US5288854A (en) 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5460945A (en) 1991-05-30 1995-10-24 Center For Blood Research, Inc. Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response
US5891841A (en) 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU4390893A (en) 1992-05-21 1993-12-13 Center For Blood Research, Inc., The A novel receptor for alpha4 integrins and methods based thereon
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US5877295A (en) 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5470953A (en) 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
GB2298520B (en) * 1995-03-03 1999-09-08 Hong Chen Fu In Heat sink device for integrated circuit
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888765A (en) 1995-06-23 1999-03-30 President And Fellows Of Harvard College Endothelial-cell specific promoter
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US5843712A (en) * 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU731817C (en) * 1996-11-27 2001-11-01 Genentech Inc. Humanized anti-CD11a antibodies
PT998486E (en) 1997-06-13 2007-08-21 Genentech Inc Protein recovery by chromatography followed by filtration upon a charged layer
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6582698B1 (en) * 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
MY122724A (en) 1999-04-13 2006-04-29 Mitsui Chemicals Inc Method for preparing living polymer in the presence of phosphazenium salt
NZ519222A (en) 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
JP3933847B2 (en) 2000-06-19 2007-06-20 ユニ・チャーム株式会社 Absorbent articles
US6951927B2 (en) 2000-07-07 2005-10-04 California Institute Of Technology Proteins with integrin-like activity

Also Published As

Publication number Publication date
US7879577B2 (en) 2011-02-01
US7160541B2 (en) 2007-01-09
US20050260192A1 (en) 2005-11-24
US7968284B2 (en) 2011-06-28
JP2004527217A (en) 2004-09-09
US20100113742A1 (en) 2010-05-06
US20110305691A1 (en) 2011-12-15
US20050182244A1 (en) 2005-08-18
US20110111528A1 (en) 2011-05-12
EP1315812A2 (en) 2003-06-04
DE60140457D1 (en) 2009-12-24
JP5113314B2 (en) 2013-01-09
WO2002018583A9 (en) 2003-10-30
WO2002018583A3 (en) 2003-01-30
US8241627B2 (en) 2012-08-14
EP1315812B1 (en) 2009-11-11
WO2002018583A2 (en) 2002-03-07
CA2417432A1 (en) 2002-03-07
CA2417432C (en) 2010-11-02
US20020123614A1 (en) 2002-09-05
US7241869B2 (en) 2007-07-10
US7674604B2 (en) 2010-03-09
ATE448306T1 (en) 2009-11-15

Similar Documents

Publication Publication Date Title
AU2001287000A1 (en) Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2005003345A3 (en) Look-through mutagenesis
ECSP055849A (en) ANTIBODY ("11C7") ANTI-NOGO A AND ITS PHARMACEUTICAL USE
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
WO2002004523A3 (en) Artificial antibody polypeptides
BR9809778A (en) Isolated polynucleotide, expression vector, isolated peptide or polypeptide, antibody, process for producing the same, antibody fragments, single chain antibodies or humanized antibodies, and anti-idiotypic antibody.
WO2002002783A3 (en) Expression vectors
ATE177758T1 (en) SYNTHETIC PEPTIDES, ANTIBODIES AGAINST THEM AND THEIR USE
IL181578A (en) Antibodies which are specifically immunoreactive with hedgehog interacting proteins and a hybridoma producing such antibodies
WO2002079394A3 (en) Synthesis and use of glycodendrimer reagents
IL167121A (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
ATE234918T1 (en) MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS P55 AND P75 AS WELL AS AGAINST TNF-ALPHA AND ITS ANALOGUES
WO2000001712A3 (en) Chemically modified proteins with a carbohydrate moiety
EP0824149A3 (en) Glutamine: fructose-6-phosphate amidotransferase (GFAT), its production and use
DE69634757D1 (en) VECTOR FOR THE EXPRESSION OF N-TERMINAL EXTENDED PROTEINS IN HEF-CELLS
SE0002835D0 (en) Method and kit for production of monoclonal antibodies
Lugovskoy et al. Functional role of Bβ‐chain N‐terminal fragment in the fibrin polymerization process
DE59709495D1 (en) Antibodies and immunoassay for the detection of MIA
KR900002074A (en) Monoclonal Antibodies Recognizing Gamma-Atrial Sodium Diuretic Polypeptides
WO2004007530A3 (en) Modified proteins stabilized in a desired conformation and methods for producing same
Velikson et al. Structural modeling of the pro-ocytocin-neurophysin precursor.
WO2001012788A3 (en) Tryptase-like polypeptide ztryp1
WO2001085937A3 (en) Regulator of g protein signalling (rgs8)
AU2003242344A1 (en) Translation templates and library thereof, proteins synthesized therefrom and protein library, constituents thereof, process for producing the same and method of using the same